Claims for Patent: RE39820

Summary for Patent: RE39820

Title:	Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Abstract:	Compounds of the formula of which, in exemplary compounds, the thienyl group is attached via the 2-position and; (a) A is 3alpha-(6beta, 7beta-epoxy)-tropanyl methobromide and R1 is 2-thienyl; (b) A is 3alpha-(6, 7dehydro)-tropanyl methobromide and R1 is 2-thienyl; (c) A is 3beta-tropanyl methobromide and R1 is 2-thienyl; and, (d) A is 3alpha-(N-isopropyl)-nortropanyl methobromide and R1 is cyclopentyl. There are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.
Inventor(s):	Rolf Banholzer, Rudolf Bauer, Richard Reichl
Assignee:	Boehringer Ingelheim Pharma GmbH and Co KG
Application Number:	US11/254,213
Patent Claims:	1. A compound of the formula wherein Q is a group of the formula —CH2—CH2—, —CH═CH— or R and R′ are each independently C1-C4-alkyl; R1 is thienyl, phenyl, cyclopentyl or cyclohexyl; and, X− is a physiologically acceptable anion. 2. A compound in accordance with claim 1, of the formula wherein R is CH3, C2H5, n-C3H7, or i-C3H7; R′ is CH3; and R1, Q and X− are as defined in claim 1. 3. A compound in accordance with claim 2 wherein R1 is thienyl. 4. A compound in accordance with claim 2 wherein X− is Br− or CH3SO3 CH3 SO 3 − . 5. A compound of the formula wherein X− is a physiologically acceptable anion. 6. A compound of the formula wherein X− is a physiologically acceptable onion. 7. A compound of the formula 8. A compound of the formula wherein R1 is 2-thienyl and A is 3α-(6,7-dehydro)-tropanyl methobromide. 9. A compound of the formula wherein R1 is 2-thienyl and A is 3β-tropanyl methobromide. 10. A compound of the formula wherein R1 is cyclopentyl and A is 3α-(N-isopropyl)-nortropanyl methobromide. 11. A method for treating chronic obstructive bronchitis which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, or 8, 9, 10 . 12. A method for treating slight to moderately severe asthma which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10. 13. A method for treating vagally induced sinus bradycardia which comprises administering, by the intravenous or oral routes, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, or 8, 9, 10 . 14. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma , which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, or 8, 9, 10 . 15. A pharmaceutical composition for oral administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, or 8, 9, 10 . 16. A pharmaceutical composition, for intravenous administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, or 8, 9, 10 . 17. A method for treating chronic obstructive bronchitis which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claim 5. 18. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis, which comprises a compound in accordance with claim 5. 19. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis, comprising an inhalation powder comprising a compound in accordance with claim 5. 1. A compound of the formula ##STR00026## wherein Q is a group of the formula .[.--CH.sub.2--CH.sub.2--,.]. --CH.dbd.CH-- or ##STR00027## R and R' are each independently C.sub.1-C.sub.4-alkyl; R.sub.1 is thienyl, phenyl, cyclopentyl or cyclohexyl; and, X.sup.- is a physiologically acceptable anion. 2. A compound in accordance with claim 1, of the formula ##STR00028## wherein R is CH.sub.3, C.sub.2H.sub.5, n-C.sub.3H.sub.7, or i-C.sub.3H.sub.7; R' is CH.sub.3; and R.sub.1, Q and X.sup.- are as defined in claim 1. 3. A compound in accordance with claim 2 wherein R.sub.1 is thienyl. 4. A compound in accordance with claim 2 wherein X.sup.- is Br.sup.- or .[.CH.sub.3SO.sub.3.]. .Iadd.CH.sub.3SO.sub.3.sub.-.Iaddend.. 5. A compound of the formula ##STR00029## wherein X.sup.- is a physiologically acceptable anion. 6. A compound of the formula ##STR00030## wherein X.sup.- is a physiologically acceptable onion. 7. A compound of the formula ##STR00031## 8. A compound of the formula ##STR00032## wherein R.sub.1 is 2-thienyl and A is 3.alpha.-(6,7-dehydro)-tropanyl methobromide. .[.9. A compound of the formula ##STR00033## wherein R.sub.1 is 2-thienyl and A is 3.beta.-tropanyl methobromide..]. .[.10. A compound of the formula ##STR00034## wherein R.sub.1 is cyclopentyl and A is 3.alpha.-(N-isopropyl)-nortropanyl methobromide..]. 11. A method for treating chronic obstructive bronchitis which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, .Iadd.or .Iaddend.8.[., 9, 10.]. . .[.12. A method for treating slight to moderately severe asthma which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10..]. 13. A method for treating vagally induced sinus bradycardia which comprises administering, by the intravenous or oral routes, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, .Iadd.or .Iaddend.8.[., 9, 10.]. . 14. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis .[.or slight to moderately severe asthma.]. , which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, .Iadd.or .Iaddend.8.[., 9, 10.]. . 15. A pharmaceutical composition for oral administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, .Iadd.or .Iaddend.8.[., 9, 10.]. . 16. A pharmaceutical composition, for intravenous administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, .Iadd.or .Iaddend.8.[., 9, 10.]. . .Iadd.17. A method for treating chronic obstructive bronchitis which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claim 5..Iaddend. .Iadd.18. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis, which comprises a compound in accordance with claim 5..Iaddend. .Iadd.19. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis, comprising an inhalation powder comprising a compound in accordance with claim 5..Iaddend.